Brazilian PM's “Dhanyawad India” for Vaccine

India is sending doses of corona vaccine to help other countries and earlier today 2 million doses to Brazil was sent.

Brazil today received two million doses of the coronavirus vaccine made in India. Brazilian President Jair M Bolsonaro, while thanking India for vaccines, said his country feels honoured to have a great partner to overcome the global obstacle by joining efforts. Brazil has been hit by a second wave of infections since November, with more than 1,000 deaths a day and a total death toll of more than 214,000 - followed by the United States alone.

Prime Minister Narendra Modi responded that India would continue to strengthen health co-operation. India sent two million doses of Covishield vaccine to Brazil on Friday. Covishield was developed by AstraZeneca and Oxford University and manufactured in large scale by the Serum Institute of India. Foreign Minister S Jaishankar has confirmed the arrival of vaccines. And have posted pictures on twitter.

The Brazilian Foreign Ministry, through the New Delhi Embassy, has made arrangements with India and the Serum Institute of India for the distribution of COVID-19 vaccine, following a letter from President Jair Bolsonaro to Prime Minister Narendra Modi on January 8. Brazilian Ambassador André Aranha Correa do Lago thanked the Serum Institute for vaccinations and "proven technology" during the march. "I thank the Serum Institute of India for the remarkable expertise shown during the shipment of this Oxford AstraZeneca vaccine in Brazil and the great appreciation and gratitude to the Government of India for their support," said Andre Aranha Corrêa do Lago.

The government has canceled the export of COVID-19 vaccines, and the first shipments will be sent to Brazil and Morocco. Over the past few days, India has shipped COVID-19 vaccines, manufactured locally, to neighboring countries including Bhutan, Maldives, Nepal, Myanmar and Bangladesh. Brazilian President Jair M Bolsonaro thanked India for the coronavirus vaccine.


The Brief. Sign up to receive the top stories you need to know right now.